Related Experiment Video

Updated: Jun 6, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Lack of association of CFD polymorphisms with advanced age-related macular degeneration

Jiexi Zeng1, Yuhong Chen, Zongzhong Tong

  • 1Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha, China.

Molecular Vision
|December 9, 2010
PubMed

Insights

This study found no significant association between complement factor D (CFD) gene variations and age-related macular degeneration (AMD) in a Caucasian population, suggesting CFD may not be a major genetic risk factor for AMD.

Area of Science:

  • Ophthalmology
  • Genetics
  • Immunology

Background:

  • Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss globally.
  • AMD pathogenesis is linked to complement cascade dysregulation, with factors like CFH, CFB, C2, and C3 implicated.
  • The role of complement factor D (CFD) in AMD susceptibility remains less understood.

Purpose of the Study:

  • To investigate the association between complement factor D (CFD) gene variations and advanced age-related macular degeneration (AMD).
  • To analyze six single nucleotide polymorphisms (SNPs) in the CFD region for their correlation with AMD in a Caucasian cohort.

Main Methods:

  • Genotyping of six selected SNPs in the CFD region was performed in 178 advanced AMD patients and 161 controls.
  • Replication analysis was conducted in an independent cohort of 445 advanced AMD patients and 190 controls.
  • Allele frequencies were compared between case and control groups using chi-squared (χ2) tests.

Main Results:

  • No significant association was detected between any of the six analyzed CFD single nucleotide polymorphisms (SNPs) and advanced age-related macular degeneration (AMD).
  • The allele frequencies for the studied CFD SNPs did not differ significantly between AMD patients and control groups in either the initial or replication cohorts.

Conclusions:

  • The study suggests that complement factor D (CFD) may not play a significant role in the genetic susceptibility to age-related macular degeneration (AMD).
  • The investigated SNPs within the CFD region do not appear to be major genetic risk factors for advanced AMD in the studied Caucasian population.
Abstract

More Related Videos

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography05:14

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography

Published on: August 11, 2023

Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration10:14

Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...